NCT06990321View on ClinicalTrials.gov

Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia

PHASE3RecruitingINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Acute Myeloid Leukemia (AML)Elderly
Interventions
DRUG

Intermediate-dose Cytarabine in Combination with Venetoclax

Elderly patients with Middle- and High-risk Acute Myeloid Leukemia who received the Intermediate-dose Cytarabine in Combination with Venetoclax at the First Hospital of Jilin University from March 1, 2024 to December 31, 2026.

Trial Locations (1)

130000

RECRUITING

The First Hospital of Jilin University, Changchun

All Listed Sponsors
lead

Yehui Tan

OTHER